Business Description
ISIN : BE0974461940
Total Employee Number:
364Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.18 | |||||
Equity-to-Asset | -0.23 | |||||
Debt-to-Equity | -3.48 | |||||
Debt-to-EBITDA | -10.16 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -3.87 | |||||
Beneish M-Score | -3.68 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2.6 | |||||
3-Year EBITDA Growth Rate | 49.8 | |||||
3-Year EPS without NRI Growth Rate | 42.7 | |||||
3-Year FCF Growth Rate | 69.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 30.28 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.74 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 65.62 | |||||
9-Day RSI | 63.71 | |||||
14-Day RSI | 62.63 | |||||
3-1 Month Momentum % | -26.33 | |||||
6-1 Month Momentum % | -87.08 | |||||
12-1 Month Momentum % | -87.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.15 | |||||
Quick Ratio | 0.98 | |||||
Cash Ratio | 0.51 | |||||
Days Inventory | 54.57 | |||||
Days Sales Outstanding | 50.91 | |||||
Days Payable | 88.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -46.6 | |||||
Shareholder Yield % | -37.11 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 63.69 | |||||
Operating Margin % | -19.06 | |||||
Net Margin % | -33.46 | |||||
EBITDA Margin % | -9.34 | |||||
FCF Margin % | -5.39 | |||||
OCF Margin % | -4.75 | |||||
ROA % | -25.37 | |||||
ROIC % | -16.3 | |||||
3-Year ROIIC % | 72.49 | |||||
ROC (Joel Greenblatt) % | -154.74 | |||||
ROCE % | -20.82 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.33 | |||||
EV-to-EBIT | -7.37 | |||||
EV-to-EBITDA | -15.18 | |||||
EV-to-Revenue | 1.42 | |||||
EV-to-Forward-Revenue | 1.14 | |||||
EV-to-FCF | -26.26 | |||||
Price-to-GF-Value | 0.36 | |||||
Earnings Yield (Greenblatt) % | -13.57 | |||||
FCF Yield % | -8.43 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MDXH
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
MDxHealth SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 111.573 | ||
| EPS (TTM) ($) | -0.72 | ||
| Beta | 1.3017 | ||
| 3-Year Sharpe Ratio | -0.54 | ||
| 3-Year Sortino Ratio | -0.66 | ||
| Volatility % | 121.94 | ||
| 14-Day RSI | 62.63 | ||
| 14-Day ATR ($) | 0.068128 | ||
| 20-Day SMA ($) | 0.690935 | ||
| 12-1 Month Momentum % | -87.48 | ||
| 52-Week Range ($) | 0.4 - 5.33 | ||
| Shares Outstanding (Mil) | 95.42 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MDxHealth SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MDxHealth SA Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 16:30 | In 175 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 174 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-12 | In 68 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 68 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-13 16:30 | 0.47 (+4.36%) | ||
| Second quarter earnings results for 2026 | 2026-08-13 | 0.47 (+4.36%) | ||
| General meeting for 2025 | 2026-05-28 | 0.75 (+2.03%) | ||
| First quarter earnings conference call for 2026 | 2026-05-13 16:30 | 1.87 (-5.56%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 1.87 (-5.56%) | ||
| Annual report for 2025 | 2026-04-03 | 2.16 (-1.82%) |
MDxHealth SA Frequently Asked Questions
Guru Commentaries on NAS:MDXH
MDxHealth (MDXH) is a prostate cancer diagnostics screening company that has shown strong revenue growth, achieving over 20% growth each of the last 12 quarters through Q2 2025. The company has a robust portfolio of non-invasive tests, including Exo DX and Confirm mdx, which provide valuable guidance for treatment decisions. Despite a recent stock drop due to confusion around growth expectations for 2026, we believe this was overdone. The stock trades at only 2x EV/Revenues, significantly lower than peers at 5-9x, indicating a strong value opportunity given its growth and margin profile. We expect the positive momentum to continue, especially after acquiring an additional prostate test.
MDxHealth (MDXH) is a prostate cancer diagnostics screening company we initially purchased at around $2 per share a year ago. Prostate is the second most diagnosed cancer type overall and the most common in men. Their portfolio includes Select mdx, Confirm mdx, Genomic Prostate Score (GPS), and the hereditary prostate cancer test. The company has a network of over 7 thousand physicians and has completed over 250 thousand tests in total. With their series of non-invasive tests, they offer physicians and patients additional guidance when making treatment decisions. MDXH has grown revenue each of the last 12 quarters at over 20% and we believe they can accelerate that rate as they recently acquired an additional prostate test. Despite the positive momentum the stock only trades at 2x EV/Revenues vs. peers at 5-9x for similar growth and margin profiles.
Press Release
Articles on MDxHealth SA
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
